TEPOTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS: A US COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Yang, M. [1 ]
Sachdev, R. [2 ]
Stargardter, M. [2 ]
Tosh, J. [3 ]
Vioix, H. [4 ]
机构：
[1] EMD Serono, Rockland, MA USA
[2] Evidera, Bethesda, MD USA
[3] Evidera, London, England
[4] Merck KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE160
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [21] Tepotinib Treatment of Patients with Skipping Mutation in Exon 14 of the MET-Gene (METex14) in non-small cell Lung Cancer: Interim Analysis of VISION Cohorts A (Primary Analysis) and C (confirmatory Analysis)
    Wermke, M.
    Griesinger, F.
    Thomas, M.
    Reinmuth, N.
    Overbeck, T.
    Alt, J.
    Henschke, S.
    Wehler, T.
    Ochsenreither, S.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Bruns, R.
    Otto, G.
    Johne, A.
    Paik, P. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 54 - 55
  • [22] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping
    Hook, E.
    Vioix, H.
    Batteson, R.
    McLean, T.
    Hatswell, A.
    VALUE IN HEALTH, 2022, 25 (12) : S420 - S420
  • [24] Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).
    Kim, So Yeon
    Bohlman, Stephen
    Yin, Jun
    Cheng, Haiying
    Walker, Phillip
    Dacic, Sanja
    Kim, Chul
    Khan, Hina
    Liu, Stephen V.
    Ma, Patrick C.
    Nagasaka, Misako
    Reckamp, Karen L.
    Abraham, Jim
    Uprety, Dipesh
    Halmos, Balazs
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)
    Kelly, R. J.
    Le, X.
    Luttropp, K.
    Yang, M.
    Liu, F.
    Huse, S.
    Ganz, M. L.
    Pfeiffer, B.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1088 - S1089
  • [26] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF TEPOTINIB WITH CAPMATINIB IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITH MET EXON 14 (METEX14) SKIPPING
    Paik, P.
    Pfeiffer, B.
    Vioix, H.
    Postma, M. J.
    VALUE IN HEALTH, 2022, 25 (12) : S28 - S28
  • [27] Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
    Spira, A.
    Krebs, M.
    Cho, B. C.
    Besse, B.
    Goldman, J.
    Janne, P.
    Lee, C. K.
    Ma, Z.
    Mansfield, A.
    Minchom, A.
    Ou, S.
    Salgia, R.
    Wang, Z.
    Gao, G.
    Curtin, J.
    Roshak, A.
    Schnepp, R.
    Thayu, M.
    Knoblauch, R.
    Trigo, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S874 - S875
  • [28] Cost-effectiveness analysis of Tumor Treating Fields treatment in Chinese patients with metastatic non-small cell lung cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [29] VALIDATING THE RESULTS OF A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
    Hatswell, A.
    Batteson, R.
    Hook, E.
    Wheat, H.
    Vioix, H.
    McLean, T.
    Alexopoulos, S.
    Baijal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S21 - S22
  • [30] Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
    Ahn, Linda
    Alexander, Terri
    Vlassak, Soetkin
    Berghoff, Karin
    Lemmens, Liesbeth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (05) : 543 - 551
12345